A Double-Blind, Placebo-Controlled, Randomized Ph III Study of Ipatasertib in Combo With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, TNBC or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Investigator: Polly Niravath, MD

Study Coordinator: Toniva Boone

Status: Enrolling

ClinicalTrials.gov Number: NCT03337724

Phone: 713.441.0686

Protocol Number: Pro00018450

Description

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) breast adenocarcinoma who are not suitable for endocrine therapy.
More to Explore
Live Chat Available